Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected ...
Zacks Investment Research on MSN

KYMR skyrockets 82.4% in a year: More upside potential in 2026?

Kymera Therapeutics, Inc. KYMR has put up a stupendous performance over the past year. Shares of this clinical-stage ...
Hosted on MSN

Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging

Kymera Therapeutics, Inc. KYMR reported a first-quarter 2025 loss of 82 cents per share, narrower than the Zacks Consensus Estimate of a loss of 92 cents. In the year-ago quarter, Kymera reported a ...